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Dear Editor, 
Not only is inflammatory bowel disease (IBD) debilitating to individuals, but the economic 
impact is high (>A$2.7 billion to the Australian economy in 2005).[1] The two main drivers of 
expenditure are hospitalisations and pharmacological treatments.[2] Several medicines are 
available for the treatment of IBD including 5-aminosalicylic acid compounds and biologic 
agents.[3] 
 
Many medicines are available to patients in Australia through the Pharmaceutical Benefits 
Scheme (PBS). The Australian government subsidies the cost of each prescription that is 
dispensed and patients contribute a co-payment.[4] Medicine use can be estimated by 
calculating the defined daily dose (DDD) per 1,000 population per day (DDD/1,000 
population/day).[5] The DDD is the assumed average maintenance dose per day for a 
medicine used for its main indication in adults.[5] This methodology enables us to compare 
different medicines and examine international consumption patterns.[5] 
 
In Australia, PBS subsidised access to biologic agents is only for those who have failed other 
therapies, with the exception of fistulising Crohn’s disease, whereby immediate biologic use 
is allowed. To obtain subsidised access to biologic agents in Crohn’s disease, the patient 
needs to fail a trial of both steroids and antimetabolite therapy. In ulcerative colitis, a 
patient with acute severe disease that fails steroid induction is allowed a three infusion 
course of infliximab but to obtain ongoing PBS access to biologic therapies, the patient 
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needs to show a failure of response to both 5-aminosalicylic acid compounds and 
antimetabolite therapy.  
 
We have characterised the use and costs of subsidising 5-aminosalicyclic acid compounds 
(sulfasalazine, mesalazine, olsalazine, and balsalazide) from 2004 to 2015 and biologic 
agents (adalimumab, infliximab and vedolizumab) from 2007 to 2015 to treat IBD in 
Australia. Only prescriptions dispensed specifically for Crohn’s Disease or ulcerative colitis 
were considered. Item numbers of these medicines were used to retrieve the number of 
dispensed prescriptions and costs for each medicine from the Medicare Australia PBS 
statistics website.[6] Data were analysed by medicine class and indication. Medicine use was 
calculated using the DDD/1,000 population/day.[5]. Medicines introduced to the PBS part-
way through the calendar year were adjusted appropriately. Data were available in the 
public domain and hence ethics approval was not required.  
 
5-Aminosalicylic acid compounds; mesalazine, sulfasalazine and olsalazine were available on 
the PBS for subsidised treatment of ulcerative colitis from 2004 to 2015, balsalazide was 
available from 1 August 2005. Dispensed use of 5-aminosalicylic acid compounds for 
ulcerative colitis increased 68% from 1.36 to 2.28 DDD/1,000 population/day (2004-2015; 
average annual increase 5.6%) (Figure 1a). In 2015, mesalazine, sulfasalazine, olsalazine and 
balsalazide accounted for 62.9%, 32.1%, 3.3% and 1.7% of 5-aminosalicylic acid compounds 
use, respectively. The dispensed use of sulfasalazine, olsalazine and balsalazide declined or 
remained relatively constant, while mesalazine use increased approximately three fold.  
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Total government expenditure on 5-aminosalicylic acid compounds for ulcerative colitis 
increased 173% from A$33.1 million in 2004 to A$90.5 million in 2015 (Figure 1b). In 2015, 
mesalazine, sulfasalazine, balsalazide and olsalazine cost the Australia government A$78.4 
million, A$8.8 million, A$1.8 million, and A$1.4 million, respectively. The introduction of the 
biologics in 2007 did not seem to alter the use of 5-aminosalicylic acid compounds. 
 
Biological agents were first subsidised for IBD in 2007. Infliximab was available to both adult 
and paediatric Crohn’s disease patients on the PBS from 1 October 2007, for fistulising 
disease from 1 August 2010, and for ulcerative colitis patients from 1 May 2014. 
Adalimumab was available to adult Crohn’s disease patients from 1 August 2008, and for 
fistulising disease from 1 April 2011, and paediatric Crohn’s disease on 1 August 2015. 
Vedolizumab was available for adult Crohn’s disease and ulcerative colitis patients from 1 
September 2015. 
 
Dispensed use of biologic agents increased 871% from 0.029 to 0.280 DDD/1,000 
population/day (2008-2015; average annual increase 109%) (Figure 2a). In 2015, biologics 
were most frequently used in adult Crohn’s disease followed by paediatric Crohn’s disease, 
fistulising Crohn’s disease, and ulcerative colitis (0.179, 0.047, 0.045 and 0.008 DDD/1,000 
population/day, respectively). In 2015, adalimumab and infliximab accounted for nearly all 
biologic use (59.3% and 37.1%, respectively). Vedolizumab was only 3.6% of biologic 
dispensed use but use has increased since it was subsidised in late 2015. Adalimumab was 
preferentially used in both adult Crohn’s disease and fistulising Crohn’s disease. From 2009 
to 2015, adalimumab use increased by an average of 48.7% per year and infliximab use 
increased by an average of 56.3% per year.  
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Total government expenditure on biologics for treatment of IBD increased over 100 fold 
from A$1.2 million in 2008 to A$163.2 million in 2015 (Figure 2b). In 2015 adalimumab, 
infliximab and vedolizumab for the treatment of IBD cost the Australia government A$86.5 
million, A$74.7 million and A$2.1 million, respectively.  
 
This is the first report of the dispensed use and government expenditure on 5-aminosalicylic 
acid compounds and biologics for the treatment of IBD in Australia. The increase in total use 
of 5-aminosalicylic acid compounds and biologic agents (68% and 871%, respectively) 
exceeded the population increase (18% to 23.5 million people) over the last decade. Based 
on these upward trajectories, the financial burden of 5-aminosalicyclic acid compounds and 
biologic agents looks set to increase.   
 
We were able to captured complete dispensed use and costs for all subsidised agents 
examined. The DDD metric enables us to compare individual medicines and temporal 
trends. The analyses of aggregated data however precludes medicine use linked to 
individual patient characteristics (e.g. sex, age, disease severity, number of individuals), 
treatment patterns (e.g. single or combination therapy, daily dosage), or health outcomes 
and disease progression. Medicare Australia does not record data on private prescriptions 
and inpatient hospital use but use in these settings is likely to be minimal. While medicine 
dispensing rather than consumption was examined these are likely to be very similar.  It was 
beyond the scope of this analysis to examine whether the increase in cost of biologics was 
offset by reductions in other direct (e.g. hospitalisations, surgery) or indirect (work absence 
and/or limitations) costs. 
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The use and costs of biologics has increased since their subsidy in 2007. Infliximab and 
adalimumab have similar effectiveness in Crohn’s disease,[7] so the higher use of 
adalimumab may be due to prescriber or patient preference and convenience. Infliximab is 
usually given as an intravenous infusion every eight weeks while adalimumab is usually 
given as a subcutaneous injection every two weeks.[8] A single-center study from the US 
reported that after adalimumab was introduced, infliximab use plateaued then 
decreased.[9]   
 
The main indication of biologic use was in Crohn’s disease, this is consistent with previous 
studies documenting a greater medical need in those with Crohn’s disease.[8] The use and 
costs of some biologics remains low: infliximab in ulcerative colitis was only subsidised in 
2014; adalimumab from December 2016; and vedolizumab in 2015 for both Crohn’s disease 
and ulcerative colitis.[4]  
 
The increased use of 5-aminosalicylic acid compounds is mostly due to increasing use of 
mesalazine. There is no difference between oral mesalazine and oral sulfasalazine in terms 
of clinical improvement or remission but mesalazine tends to be better tolerated.[3] The 
subsidised use of mesalazine first requires that the patient show an intolerance or non-
response to sulfasalazine (which is much cheaper). The increase in use and costs of 5-
aminosalicylic acid compounds seen in this study may be associated with an increase in the 
prevalence of IBD (particularly ulcerate colitis) in Australia. Most patients with ulcerative 
colitis will commence on a 5-aminosalicylic acid compound, and the vast majority likely 
remain on this agent even if other medications are commenced. There may also be a 
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perception that sulfasalazine is the inferior drug and a preference among prescribers may 
exist to either go directly to mesalazine, or to have a very low threshold for the switch. 
More education may be required among prescribers that sulfasalazine is not inferior if it is 
tolerated. A genuine trial of sulfasalazine first before changing to mesalazine should be 
strongly encouraged; also clinicians should consideration using enteric coated formulations 
in those with dyspeptic symptoms. Our results are consistent with the increased use of 5-
aminosalicylic acid compounds over two decades to 2010 in the UK.[10] The subsidy of 
infliximab for ulcerative colitis in 2014 does not seem to have affected the use of 5-
aminosalicylic acid compounds, which is as expected given that 5-aminosalicylic acid 
compounds use is a prerequisite to qualify for biologic therapy.  
 
The increasing financial burden of treating IBD is largely attributed to the cost of biologic 
therapy. Inflectra, a biosimilar for infliximab, was subsidised in late 2015.[4] This has 
subsequently reduced the product cost of infliximab by 24% (A$751.70 in 2015; A$574.85 in 
2016).[4] The patent for adalimumab expires in 2018 so we will likely see further biosimilar 
agents and reduced costs in the future.[11] It will be noteworthy whether the costs of 
increasing use of biologic agents will be offset by the introduction of cheaper biosimilar 
agents. The earlier and more widespread use of biologic agents may well produce cost 
savings in other areas of patient care, which should also be taken into consideration when 
assessing the cost of IBD treatment. 
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Figure legends  
Figure 1: Dispensed use (defined daily dose [DDD] per 1,000 population per day) (a) and cost 
to government (A$) (b) for the four individual 5-aminosalicylic acids for ulcerative colitis. 
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Figure 2: Dispensed use (defined daily dose [DDD] per 1,000 population per day) for (a) 
adalimumab across different indications and for adalimumab and infliximab in total and (b) 
infliximab across different indications and for adalimumab and infliximab in total; Cost to 
government (A$) of (c) adalimumab across different indications and for adalimumab and 
infliximab in total and (d) infliximab across different indications and for adalimumab and 
infliximab in total in total. Results for vedolizumab not provided as first subsidised in 2015. 
Indications for the biologics include Crohn's disease (CD), Crohn's disease fistulising (CDF), 
Crohn's disease paediatric (CDP), and ulcerative colitis (UC). 
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